SUBSCRIBE
SUBSCRIBE
Kate Goodwin

Kate Goodwin

Contributing Writer | News & Features

Kate Goodwin hails from a background primarily in marketing. A passion for health sciences and writing led her to the biopharma news world, and she’s never looked back. She’s been writing for BioSpace for more than two years with a focus on cutting edge research, Alzheimer’s disease and pediatrics. Her free time is filled by her husband, children, Beagles, books, crochet and creative writing. She can be reached at kate.goodwin@biospace.com.

Deals
Biopharma VC Funding in Q2 Reaches Highest Quarterly Level Since 2022
Venture capital in the sector hit $9.2 billion in the second quarter of 2024, up from $7.4 billion in Q1, while exits fell on a slower M&A cycle and picky IPO market.
August 23, 2024
 · 
3 min read
 · 
Kate Goodwin
Novartis head office building in Dorval, Quebec, Canada
Business
Novartis, Versant Launch RNA Kidney Medicines—Focused Borealis
Looking to build on the success of Chinook Therapeutics, founded by Versant in 2019 and acquired by Novartis last year, the companies on Thursday launched Borealis Biosciences with $150 million in funding to develop RNA therapeutics for kidney diseases.
August 22, 2024
 · 
2 min read
 · 
Kate Goodwin
Johnson & Johnson's business center in Switzerland
FDA
J&J’s Rybrevant Combo Gets FDA Approval as First Chemo-Free Treatment for NSCLC
Johnson & Johnson announced Tuesday that the FDA has approved Rybrevant with Lazcluze as a first-line chemotherapy-free treatment for patients with EGFR-mutated non-small cell lung cancer.
August 20, 2024
 · 
1 min read
 · 
Kate Goodwin
Pictured: Novavax/Getty Images, STR/NurPhoto
Business
Novavax Misses Q2 Revenue Estimate, Cuts 2024 Forecast on COVID-19 Vaccine Sales
The vaccine maker on Thursday reported $415.5 million in total revenue in the second quarter, lower than the analyst consensus of $458.6 million.
August 8, 2024
 · 
1 min read
 · 
Kate Goodwin
South San Francisco, CA, USA - May 1, 2022: Exterior view of the Merck Researches Laboratories in South San Francisco, California. Merck & Co., Inc. is a global pharmaceutical company headquartered in Rahway, New Jersey. The company does business as Merck Sharp & Dohme (MSD) outside the United States and Canada.
Deals
Daiichi Pays Merck $170M for T-Cell Engager, Expands ADC Partnership
After dropping $4 billion on a deal with the Japanese company last year, Merck is getting back some of its investment as Daiichi Sankyo buys into a Phase I/II T-cell engager therapy acquired from Harpoon Therapeutics.
August 6, 2024
 · 
1 min read
 · 
Kate Goodwin
The Philadelphia skyline
Alzheimer’s disease
New Leqembi Data Illuminate Longer-Term Effects, Tau Reduction
Eisai presented a plethora of data on the drug at the Alzheimer’s Association International Conference, including a study showing the consequences of pausing treatment.
July 31, 2024
 · 
5 min read
 · 
Kate Goodwin
Adaptimmune sign on a building
Regulatory
Adaptimmune Gears Up for Potential Approval of First-in-Class Engineered T Cell Therapy
After more than a decade devoid of therapeutic advancements, a first-in-class T cell receptor therapy could be on the immediate horizon for synovial sarcoma patients.
July 29, 2024
 · 
5 min read
 · 
Kate Goodwin
Manhattan, New York USA - July 9, 2011: Pfizer letter sign on the building's Headquarters. Pfizer's is the largest pharmaceutical company in the world.
Drug Development
Pfizer’s Hemophilia A Gene Therapy Candidate Gets Phase III Win
The company’s candidate, giroctocogene fitelparvovec, met its primary and key secondary objectives of superiority compared to the standard treatment of regular Factor VIII infusions.
July 24, 2024
 · 
2 min read
 · 
Kate Goodwin
GSK's headquarters office building in Poznan, Poland
Drug Development
GSK’s Dovato Matches Efficacy of Gilead’s Biktarvy in Head-to-Head HIV Trial
In the largest study of its kind, GSK’s two-drug regimen Dovato demonstrated non-inferior efficacy compared to Gilead Sciences’ three-drug regimen Biktarvy for the treatment of HIV-1.
July 23, 2024
 · 
2 min read
 · 
Kate Goodwin
Pictured: Exterior of a Samsung location in San Jose, California/iStock, JHVEPhoto
FDA
Samsung Bioepis Gets FDA Approval for Biosimilar to AstraZeneca’s Soliris
The South Korean company’s Epysqli is now FDA-approved for paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome in the U.S., having grabbed the lead in the Soliris biosimilar market in Europe.
July 22, 2024
 · 
1 min read
 · 
Kate Goodwin
Pictured: FDA Headquarters, iStock, Grandbrothers
FDA
Phathom Scores Non-Erosive GERD Approval for Heartburn Drug
Already approved for erosive gastroesophageal reflux disease, Phathom’s Voquenza is now authorized to treat patients with non-erosive GERD.
July 18, 2024
 · 
1 min read
 · 
Kate Goodwin
NGM Bio headquarters in San Francisco, California
Business
Newly Private NGM Bio Raises $122M for Registrational PSC Study
After completing a buyout transaction with The Column Group to remove it from the stock exchange, NGM Bio has raised a $122M Series A to fund a registrational study for a rare liver disease drug and a Phase II trial in hyperemesis gravidarum.
July 17, 2024
 · 
1 min read
 · 
Kate Goodwin
3D rendering of an antibody drug conjugate
Antibody-Drug Conjugate (ADCs)
Ipsen Inks Potential $1B First-in-Class ADC Deal With Foreseen
In its second antibody-drug conjugate licensing agreement this year, Ipsen has secured exclusive rights to Foreseen Biotechnology’s FS001, which targets a novel antigen expressed across a range of solid tumors.
July 11, 2024
 · 
1 min read
 · 
Kate Goodwin
Sign in front of Pfizer in Quebec, Canada
Business
Pfizer CSO Mikael Dolsten to Step Down After 15 Years Driving R&D
The pharma giant announced Tuesday that Mikael Dolsten is leaving his role as chief science officer after more than 15 years. Pfizer is conducting an external search for a replacement with Dolsten staying on to assist in finding his replacement over next several months.
July 9, 2024
 · 
1 min read
 · 
Kate Goodwin
A white blood cell charging an ADC/
Drug Development
Drug Developers Tap the Immune System to Supercharge ADCs
With the antibody drug conjugate market projected to hit $28 billion by 2028, some companies are looking to harness the drugs for immunotherapy.
July 8, 2024
 · 
7 min read
 · 
Kate Goodwin
Load More